MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jaci.2020.07.021

Медицинская библиотека · The Journal of allergy and clinical immunology · 2020

Rituximab and antimetabolite treatment of granulomatous and lymphocytic interstitial lung disease in common variable immunodeficiency.

Verbsky James W, Hintermeyer Mary K, Simpson Pippa M, Feng Mingen, Barbeau Jody, Rao Nagarjun, Cool Carlyne D, Sosa-Lozano Luis A, Baruah Dhiraj, Hammelev Erin, Busalacchi Alyssa, Rymaszewski Amy, Woodliff Jeff, Chen Shaoying, Bausch-Jurken Mary, Routes John M

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Granulomatous and lymphocytic interstitial lung disease (GLILD) is a life-threatening complication in patients with common variable immunodeficiency (CVID), but the optimal treatment is unknown.

OBJECTIVE

Our aim was to determine whether rituximab with azathioprine or mycophenolate mofetil improves the high-resolution computed tomography (HRCT) chest scans and/or pulmonary function test results in patients with CVID and GLILD.

METHODS

A retrospective chart review of clinical and laboratory data on 39 patients with CVID and GLILD who completed immunosuppressive therapy was performed. Chest HRCT scans, performed before therapy and after the conclusion of therapy, were blinded, randomized, and scored independently by 2 radiologists. Differences between pretreatment and posttreatment HRCT scan scores, pulmonary function test results, and lymphocyte subsets were analyzed. Whole exome sequencing was performed on all patients.

RESULTS

Immunosuppressive therapy improved patients' HRCT scan scores (P < .0001), forced vital capacity (P = .0017), FEV1 (P = .037), and total lung capacity (P = .013) but not their lung carbon monoxide diffusion capacity (P = .12). Nine patients relapsed and 6 completed retreatment, with 5 of 6 of these patients (83%) having improved HRCT scan scores (P = .063). Relapse was associated with an increased number of B cells (P = .016) and activated CD4 T cells (P = .016). Four patients (10%) had pneumonia while undergoing active treatment, and 2 patients (5%) died after completion of therapy. Eight patients (21%) had a damaging mutation in a gene known to predispose (TNFRSF13B [n = 3]) or cause a CVID-like primary immunodeficiency (CTLA4 [n = 2], KMT2D [n = 2], or BIRC4 [n = 1]). Immunosuppression improved the HRCT scan scores in patients with (P = .0078) and without (P < .0001) a damaging mutation.

CONCLUSIONS

Immunosuppressive therapy improved the radiographic abnormalities and pulmonary function of patients with GLILD. A majority of patients had sustained remissions.

Для цитирования: Verbsky James W, Hintermeyer Mary K, Simpson Pippa M, Feng Mingen, Barbeau Jody, Rao Nagarjun, Cool Carlyne D, Sosa-Lozano Luis A, Baruah Dhiraj, Hammelev Erin, Busalacchi Alyssa, Rymaszewski Amy, Woodliff Jeff, Chen Shaoying, Bausch-Jurken Mary, Routes John M. Rituximab and antimetabolite treatment of granulomatous and lymphocytic interstitial lung disease in common variable immunodeficiency.. The Journal of allergy and clinical immunology. 2020. DOI: 10.1016/j.jaci.2020.07.021.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.